Immunotherapy in Patients With Poor Performance Status: The Jury Is Still Out on This Special Population

JCO Oncol Pract. 2021 Sep;17(9):583-586. doi: 10.1200/OP.21.00397. Epub 2021 Jul 23.

Authors

Ali Raza Khaki¹, Chad Glisch¹, Laura A Petrillo¹

Affiliation

¹ Ali Raza Khaki, MD, MS, Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA; Chad Glisch, MD, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; and Laura A. Petrillo, MD, Division of Palliative Care and Geriatrics, Department of Medicine, Massachusetts General Hospital, Boston, MA.

PMID: 34297600
DOI: 10.1200/OP.21.00397

No abstract available

Publication types

Letter
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung*
Humans
Immunologic Factors
Immunotherapy
Lung Neoplasms*

Substances

Immunologic Factors